Financial News
Articles published by Immuneering Corporation
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
![](https://ml.globenewswire.com/media/61c16b4b-5f46-45a8-9336-31739a3a520b/small/immuneering-color-logo-cmyk-resized-jpg.jpg)
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
February 20, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Immuneering Announces Participation in February Investor Conferences
February 01, 2024
Via GlobeNewswire
Tickers
IMRX
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
![](https://ml.globenewswire.com/media/53f47482-3967-413c-b106-7062bb5140f7/small/immuneering-logo-1-png.png)
Via GlobeNewswire
Tickers
IMRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.